Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers

Abstract Background Patient-derived glioma stem-like cells (GSCs) have become the gold-standard in neuro-oncological research; however, it remains to be established whether loss of in situ microenvironment affects the clinically-predictive value of this model. We implemented a GSC monolayer system t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Ioannis Ntafoulis, Anne Kleijn, Jie Ju, Kevin Jimenez-Cowell, Federica Fabro, Michelle Klein, Romain Tching Chi Yen, Rutger K. Balvers, Yunlei Li, Andrew Stubbs, Trisha V. Kers, Johan M. Kros, Sean E. Lawler, Laurens V. Beerepoot, Andreas Kremer, Ahmed Idbaïh, Maïté Verreault, Annette T. Byrne, Alice C. O’Farrell, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H.M. Prehn, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Martin J. van den Bent, Clemens M.F. Dirven, Sieger Leenstra, Franck Bielle, Emie Quissac, Jane Cryan, Francesca Brett, Alan Beausang, Orna Bacon, Steve MacNally, Philip J. O’Halloran, James Clerkin, Martine L.M. Lamfers
Aineistotyyppi: Artigo
Kieli:englanti
Julkaistu: 2023
Linkit:https://doi.org/10.1038/s41416-023-02402-y
https://www.nature.com/articles/s41416-023-02402-y.pdf
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Internet

https://doi.org/10.1038/s41416-023-02402-y
https://www.nature.com/articles/s41416-023-02402-y.pdf

Samankaltaisia teoksia